Numerous outlets reported on Telum Therapeutics’ announcement that it raised €18 million in a Series A financing round led by AMR Action Fund.
EU-Startups reported that Telum’s announcement “sits alongside several sizeable and relevant European BioTech and drug discovery financings this year.” The article also included a quote from AMR Action Fund CEO Henry Skinner, who said:
"Acinetobacter baumannii is one of the most formidable bacterial threats in modern medicine. It is clinically challenging, often resistant to first-line therapies, and a pathogen for which progress has been slow and difficult to achieve. We are encouraged by Telum’s novel approach and pleased to support the team as they work to bring forward a new treatment option for patients with life-threatening infections.”
Read the full article here.